Alcon Earnings Reports

Alcon delivered solid second-quarter 2025 results with sales reaching $2.6 billion, a 4% increase on a reported basis. Diluted EPS was $0.35, and core diluted EPS stood at $0.76. The company generated strong free cash flow in the first half of the year and returned $287 million to shareholders. Strategic moves included the launch of Tryptyr for dry eye disease and the announced acquisition of STAAR Surgical to expand its myopia correction portfolio.

Alcon posted stable revenues of $2.5B in Q1 2025, with net income rising to $350M. Adjusted EPS was $0.73, reflecting continued innovation-led performance despite market softness in the US.

Alcon achieved net sales of $2.5 billion in Q4 2024, a 6% increase over the previous year. Operating income rose significantly to $395 million, with an operating margin expansion of 7 percentage points. The company reported diluted EPS of $0.57 and core diluted EPS of $0.72.